Literature DB >> 28445776

Antimicrobial resistance in the Bacteroides fragilis group in faecal samples from patients receiving broad-spectrum antibiotics.

Kia Cirkeline Møller Hansen1, Simon A F Schwensen2, Daniel Pilsgaard Henriksen3, Ulrik Stenz Justesen4, Thomas Vognbjerg Sydenham5.   

Abstract

Members of the Bacteroides fragilis group are opportunistic pathogens and cause severe infections including bacteraemia. As increased levels of antimicrobial resistance in B. fragilis group bacteria can be detected years after administration of specific antibiotics, monitoring antimicrobial susceptibility in the gut microbiota could be important. The objectives of this study were to 1) investigate the distribution of species and the occurrence of reduced antimicrobial susceptibility in the B. fragilis group from patients treated at departments with a high level of antibiotic use, 2) to determine the prevalence of the carbapenem resistance gene cfiA in B. fragilis in this patient group, and 3) to determine the association between previous antibiotic treatment and reduced susceptibility to clindamycin, meropenem, metronidazole, and piperacillin-tazobactam. Consecutive faecal samples (n = 197) were collected from patients at the departments of haematology, oncology, and infectious diseases at Odense University Hospital, Denmark. Three colonies from each sample were identified by Matrix Assisted Lazer Desorption Ionization Time of Flight Mass Spectrometry and isolates were screened for resistance to clindamycin, meropenem, metronidazole, and piperacillin-tazobactam. B. fragilis isolates were tested for the cfiA metallo-beta-lactamase gene. Fisher's Exact test was used to test for correlation between antimicrobial exposure and reduced susceptibility. A total of 359 isolates were tested for reduced susceptibility. Of these 28%, 5%, <1%, and 11% were intermediate susceptible or resistant to clindamycin, meropenem, metronidazole, and piperacillin-tazobactam respectively. Three metronidazole resistant Bacteroides spp. were isolated. The proportion of B. fragilis belonging to division II (cfiA+) was 5.3%. Previous exposure to meropenem was associated with reduced susceptibility to meropenem (p= 0.001). In conclusion, antimicrobial resistance is prevalent and the distribution of species appears to be affected in the B. fragilis group from patients receiving broad-spectrum antibiotics, with meropenem exposure being associated with meropenem resistance.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antimicrobial resistance; Bacteroides fragilis group; Faecal microbiota

Mesh:

Substances:

Year:  2017        PMID: 28445776     DOI: 10.1016/j.anaerobe.2017.04.013

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  10 in total

1.  Evaluation of Aminoglycoside and Carbapenem Resistance in a Collection of Drug-Resistant Pseudomonas aeruginosa Clinical Isolates.

Authors:  Selina Y L Holbrook; Sylvie Garneau-Tsodikova
Journal:  Microb Drug Resist       Date:  2017-12-20       Impact factor: 3.431

2.  Evaluation of the genetic relatedness of Bacteroides fragilis isolates by TRs analysis.

Authors:  Niloofar Khodaei; Behrooz Sadeghi Kalani; Maryam Zamani; Rokhsareh Mohammadzadeh; Malihe Talebi; Tahmine Narimani; Negar Narimisa; Faramarz Masjedian Jazi
Journal:  Iran J Basic Med Sci       Date:  2020-10       Impact factor: 2.699

3.  Antimicrobial susceptibility against metronidazole and carbapenem in clinical anaerobic isolates from Pakistan.

Authors:  Yusra Shafquat; Kauser Jabeen; Joveria Farooqi; Kiran Mehmood; Seema Irfan; Rumina Hasan; Afia Zafar
Journal:  Antimicrob Resist Infect Control       Date:  2019-06-14       Impact factor: 4.887

4.  Risk factors for acquisition of carbapenem-resistance during treatment with carbapenem in the intensive care unit: a prospective study.

Authors:  François Labaste; Julia Grossac; Fanny Vardon Bounes; Jean-Marie Conil; Stéphanie Ruiz; Thierry Seguin; Marion Grare; Olivier Fourcade; Vincent Minville; Bernard Georges
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-09-03       Impact factor: 3.267

5.  Clinico-microbiological profile of Bacteroides fragilis with focus on molecular detection of emerging resistance.

Authors:  Akshita Gupta; Padmaja A Shenoy; Ajay Kumar; Kiran Chawla
Journal:  Indian J Med Res       Date:  2021-05       Impact factor: 5.274

6.  A novel Bacteroides metallo-β-lactamase (MBL) and its gene (crxA) in Bacteroides xylanisolvens revealed by genomic sequencing and functional analysis.

Authors:  József Sóki; Uwe Lang; Ulrike Schumacher; István Nagy; Ágnes Berényi; Tamás Fehér; Katalin Burián; Elisabeth Nagy
Journal:  J Antimicrob Chemother       Date:  2022-05-29       Impact factor: 5.758

7.  Higher Prevalence of Multi-Antimicrobial Resistant Bacteroides spp. Strains Isolated at a Tertiary Teaching Hospital in China.

Authors:  Yanyan Wang; Yanqiu Han; Huimin Shen; Yingying Lv; Wenqi Zheng; Junrui Wang
Journal:  Infect Drug Resist       Date:  2020-05-27       Impact factor: 4.003

8.  Compositional and functional differences of the mucosal microbiota along the intestine of healthy individuals.

Authors:  Stefania Vaga; Sunjae Lee; Boyang Ji; Anna Andreasson; Nicholas J Talley; Lars Agréus; Gholamreza Bidkhori; Petia Kovatcheva-Datchary; Junseok Park; Doheon Lee; Gordon Proctor; Stanislav Dusko Ehrlich; Jens Nielsen; Lars Engstrand; Saeed Shoaie
Journal:  Sci Rep       Date:  2020-09-11       Impact factor: 4.379

9.  Narratives of veterinary drug use in northern Tanzania and consequences for drug stewardship strategies in low-income and middle-income countries.

Authors:  Mark Caudell; Peter E Mangesho; Elibariki R Mwakapeje; Alejandro Dorado-García; Emmanuel Kabali; Cortney Price; Moses OleNeselle; Tabitha Kimani; Folorunso O Fasina
Journal:  BMJ Glob Health       Date:  2022-01

10.  Septic arthritis caused by Bacteroides thetaiotaomicrom: A case report and review.

Authors:  D Brandariz-Núñez; J Gálvez-López
Journal:  Rev Esp Quimioter       Date:  2021-10-05       Impact factor: 1.553

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.